Want to see OCS full AI Analyst Report?
Top Page
Oculis Holding
(NASDAQ:OCS)
Select Model
Select Model
Rating:52Neutral
Price Target:
$13.50
▲(21.29% Upside)
Action:Reiterated
Date:08/19/26
The score is primarily constrained by weak operating performance and sustained cash burn despite minimal revenue, partially offset by a strong, low-leverage balance sheet. Technicals are mixed (better short-term than long-term), while valuation is less supportive due to negative earnings and no dividend.
Positive Factors
Strong balance sheet and low leverage
Substantial equity, assets, and minimal leverage provide financial flexibility to fund clinical programs and absorb development uncertainty without immediate dependence on debt markets.
Negative Factors
Minimal and declining commercial revenue
Very limited revenue shows the business remains dependent on successfully commercializing pipeline assets. Until launches generate scale, fixed development costs will continue to pressure margins and earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet and low leverage
Substantial equity, assets, and minimal leverage provide financial flexibility to fund clinical programs and absorb development uncertainty without immediate dependence on debt markets.
Read all positive factors
Oculis Holding (OCS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$890.79M
Dividend YieldN/A
Average Volume (3M)428.82K
Price to Earnings (P/E)―
Beta (1Y)0.87
Revenue GrowthN/A
EPS Growth34.21%
CountryUS
Employees60
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.40
Shares Outstanding67,792,175
10 Day Avg. Volume294,756
30 Day Avg. Volume428,824
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$35.56Price Target Upside219.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.55
Revenue Forecast (FY)$859.82K
Oculis Holding Business Overview & Revenue Model
Company Description
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A ke...
How the Company Makes Money
null...
Oculis Holding Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
76
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 243.00K | 0.00 | 686.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 85.57K | 0.00 | -51.40M | 0.00 | 0.00 | 0.00 |
| EBITDA | -78.50M | -93.37M | -85.53M | -87.09M | -31.90M | -13.17M |
| Net Income | -79.66M | -94.51M | -85.78M | -88.80M | -38.70M | -18.55M |
Balance Sheet | ||||||
| Total Assets | 250.34M | 236.23M | 120.35M | 114.35M | 37.06M | 58.04M |
| Cash, Cash Equivalents and Short-Term Investments | 8.00K | 213.25M | 98.66M | 91.65M | 19.79M | 46.28M |
| Total Debt | 2.54M | 2.32M | 1.18M | 605.00K | 123.08M | 114.27M |
| Total Liabilities | 31.00M | 39.94M | 46.97M | 20.63M | 135.05M | 119.00M |
| Stockholders Equity | 219.34M | 196.29M | 73.38M | 93.73M | -97.99M | -60.95M |
Cash Flow | ||||||
| Free Cash Flow | -66.05M | -62.51M | -47.73M | -53.89M | -28.62M | -13.85M |
| Operating Cash Flow | -65.87M | -62.22M | -47.50M | -53.84M | -25.07M | -13.82M |
| Investing Cash Flow | -69.94M | -59.38M | -17.56M | -54.21M | -3.55M | -28.00K |
| Financing Cash Flow | 131.68M | 178.60M | 54.03M | 129.67M | 1.71M | 55.19M |
Oculis Holding Technical Analysis
Neutral
11.13
Price Trends
12.36
Positive
18.98
Negative
21.38
Negative
Market Momentum
0.11
Negative
54.46
Neutral
66.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OCS, the sentiment is Neutral. The current price of 11.13 is below the 20-day moving average (MA) of 12.34, below the 50-day MA of 12.36, and below the 200-day MA of 21.38, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 54.46 is Neutral, neither overbought nor oversold. The STOCH value of 66.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OCS.
Oculis Holding Risk Analysis
Oculis Holding disclosed 95 risk factors in its most recent earnings report. Oculis Holding reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oculis Holding Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $10.18B | -29.03 | -34.15% | ― | -100.00% | -5.32% | |
54 Neutral | $9.50B | -54.61 | -24.32% | ― | ― | 28.51% | |
52 Neutral | $890.79M | -7.49 | -42.92% | ― | ― | 34.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $375.18M | -2.40 | -48.40% | ― | 15.98% | -40.75% | |
46 Neutral | $465.55M | -1.42 | -135.81% | ― | -94.63% | -39.78% | |
46 Neutral | $547.46M | -2.53 | -256.67% | ― | 4.08% | -343.67% |
* Healthcare Sector Average
OCS
Oculis Holding
13.09
-4.70
-26.45%
EYPT
EyePoint Pharmaceuticals
5.32
-6.27
-54.10%
SYRE
Spyre Therapeutics
106.49
89.91
542.28%
PRAX
Praxis Precision Medicines
375.94
329.00
700.89%
SPRY
ARS Pharmaceuticals
5.51
-8.00
-59.25%
UPB
Upstream Bio, Inc.
6.97
-9.76
-58.34%
Oculis Holding Corporate Events
Oculis to Acquire Full Rights to Privosegtor in Asset Deal with Accure Therapeutics
Aug 10, 2026
On August 10, 2026, Oculis Holding AG announced it had signed an asset purchase agreement with Spain-based Accure Therapeutics to acquire all worldwide development and commercial rights to Privosegtor (ACT-01) and a separate early-stage neurology ...
Oculis Holding Reports Strong Equity Base and Updates SEC Risk Factors in Q2 2026 Filing
Aug 6, 2026
On August 6, 2026, Oculis Holding AG reported unaudited financial results for the three- and six-month periods ended June 30, 2026, showing total assets of CHF 250.3 million and shareholders’ equity of CHF 219.3 million, up from year-end 202...
Oculis Updates Investor Presentation, Emphasizing Late-Stage Neuro-Ophthalmic Pipeline and Cash Runway
Jun 25, 2026
On June 25, 2026, Oculis Holding AG reported that it had updated its corporate presentation for use in meetings with investors, analysts and other stakeholders. The refreshed June 2026 deck highlights the company’s late-stage pipeline and fi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.